Hemato Oncology Testing Market Report 2025

The hemato oncology testing market size has grown rapidly in recent years. It will grow from $3.5 billion in 2024 to $3.96 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to increasing cancer incidence, growing awareness and screening programs, rising healthcare expenditure, increasing adoption of personalized medicine, and increasing incidence of blood disorders.

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $6.83 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to personalized medicine trends, integration of artificial intelligence, rising geriatric population, advancements in genomic research, and rising demand for early cancer detection. Major trends in the forecast period include technological advancements in genomic testing, liquid biopsy for non-invasive testing, collaborations and partnerships in the industry, regulatory landscape and standardization, and technological advancements.

The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. As an illustration, the American Cancer Society estimates that in 2023, leukemia is expected to impact approximately 59,610 Americans, leading to 23,710 deaths. Additionally, non-Hodgkin lymphoma is projected to affect 80,550 individuals in the United States, resulting in 20,180 deaths. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.

The increasing healthcare expenditure is projected to drive the growth of the hemato-oncology testing market in the coming years. Healthcare expenditure refers to the total funds, both public and private, allocated to the healthcare sector within a specific geographical area, country, or economy over a defined period. Proper allocation of these funds towards hemato-oncology testing enhances diagnostic accuracy, enables personalized treatment approaches, and improves patient outcomes in the complex field of hematopoietic tumors. For example, a report from the Office for National Statistics, a UK-based government department, revealed in May 2024 that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth of only 0.9% in 2022. Therefore, the rise in healthcare expenditure is fueling the growth of the hemato-oncology testing market.

Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.

Major companies in the hemato-oncology testing market are adopting a strategic partnership approach to supplement their hemato-oncology portfolio. Strategic partnerships involve leveraging mutual strengths and resources to achieve shared benefits and success. An instance of this is the collaboration between Servier Laboratories and QIAGEN N.V. to develop an mIDH1 companion diagnostic test. This test is intended to complement Servier's AML therapies by swiftly identifying patients with IDH1 gene mutations using a PCR-based diagnostic test. QIAGEN, a Germany-based molecular diagnostics company, will develop and validate this test under the Master Cooperation Agreement.

In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.

Major companies operating in the hemato oncology testing market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health.

North America was the largest region in the hemato oncology testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.

The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.

The hemato oncology testing market research report is one of a series of new reports that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with hemato oncology testing market share, detailed hemato oncology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.